RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Artelo Biosciences Stock

Artelo Biosciences P/S 2024

Artelo Biosciences P/S

0

Ticker

ARTL

ISIN

US04301G2012

WKN

A2PNJU

As of Sep 27, 2024, Artelo Biosciences's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Artelo Biosciences P/S history

Artelo Biosciences Aktienanalyse

What does Artelo Biosciences do?

Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company was founded in 2011 and is headquartered in Manchester, UK, with a branch office in San Diego, USA. Artelo Biosciences Inc began with the discovery of new drug candidates based on the body's endocannabinoid system, which plays a crucial role in regulating various physiological processes such as pain, inflammation, mood, and appetite. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies for the treatment of cancer and inflammatory diseases. Artelo Biosciences Inc operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. In cancer therapy, the company focuses on the development of new drugs for the treatment of solid tumors, particularly triple-negative breast cancer (TNBC), a highly aggressive type of cancer for which there are currently limited therapy options. Artelo Biosciences Inc has several promising drug candidates, including ART27.13, a synthetic cannabinoid receptor agonist that has shown in preclinical studies to inhibit the growth of TNBC cells. In inflammation inhibition, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of diabetes, obesity, and inflammatory bowel diseases. The company has several promising drug candidates, including ART26.12, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce inflammation in the intestine and improve insulin sensitivity. In neurological therapy, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of anxiety and pain. The company has several promising drug candidates, including ART12.11, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce anxiety and inhibit pain perception. Artelo Biosciences Inc closely collaborates with leading academic institutions and research centers to develop and test its drug candidates. The company has a strong research and development department composed of highly qualified scientists and clinicians. It also has an effective licensing and marketing strategy to bring its products to market. In summary, Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies. The company operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. Artelo Biosciences Inc has its own patents and licenses, a strong research and development department, and an effective licensing and marketing strategy to bring its products to market. Artelo Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Artelo Biosciences's P/S Ratio

Artelo Biosciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Artelo Biosciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Artelo Biosciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Artelo Biosciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Artelo Biosciences stock

What is the price-to-earnings ratio of Artelo Biosciences?

The price-earnings ratio of Artelo Biosciences is currently 0.

How has the price-earnings ratio of Artelo Biosciences changed compared to last year?

The price-to-earnings ratio of Artelo Biosciences has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Artelo Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Artelo Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Artelo Biosciences affect the company?

An increase in the price-earnings ratio of Artelo Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Artelo Biosciences affect the company?

A decrease in the price-earnings ratio of Artelo Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Artelo Biosciences?

Some factors that influence the price-earnings ratio of Artelo Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Artelo Biosciences pay?

Over the past 12 months, Artelo Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Artelo Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Artelo Biosciences?

The current dividend yield of Artelo Biosciences is .

When does Artelo Biosciences pay dividends?

Artelo Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Artelo Biosciences?

Artelo Biosciences paid dividends every year for the past 0 years.

What is the dividend of Artelo Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Artelo Biosciences located?

Artelo Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Artelo Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Artelo Biosciences from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Artelo Biosciences pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Artelo Biosciences in the year 2023?

In the year 2023, Artelo Biosciences distributed 0 USD as dividends.

In which currency does Artelo Biosciences pay out the dividend?

The dividends of Artelo Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Artelo Biosciences

Our stock analysis for Artelo Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Artelo Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.